Evidence map›Paper›PMID 35090094›Full record

ArticleClinical and translational medicine2022

Multi-omic landscaping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson's disease.

Lucas Caldi Gomes, Ana Galhoz, Gaurav Jain, Anna-Elisa Roser, Fabian Maass, Eleonora Carboni, Elisabeth Barski, Christof Lenz, Katja Lohmann, Christine Klein and 4 more

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Characterization of Isolated Human Astrocytes from Aging Brain.International journal of molecular sciences · 2025
    Article
  11. New Multiomic Studies Shed Light on Cellular Diversity and Neuronal Susceptibility in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Review
  12. Article
  13. Review
  14. An Overview of Epigenetic Changes in the Parkinson's Disease Brain.International journal of molecular sciences · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lucas Caldi GomesDepartment of Neurology, Rechts der Isar Hospital, Technical University of Munich, München, Germany.ORCID 0000-0003-4959-2169
Ana GalhozHelmholtz Zentrum München GmbH - German Research Center for Environmental Health, Institute of Computational Biology, Neuherberg, Germany.ORCID 0000-0001-7402-5292
Gaurav JainDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.ORCID 0000-0003-0987-1323
Anna-Elisa RoserDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0001-6233-1567
Fabian MaassDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0002-4077-2852
Eleonora CarboniDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0003-1354-1239
Elisabeth BarskiDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Christof LenzInstitute of Clinical Chemistry, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0002-0946-8166
Katja LohmannInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.ORCID 0000-0002-5121-1460
Christine KleinInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.ORCID 0000-0003-2102-3431
Mathias BährDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0002-9570-1592
André FischerDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.ORCID 0000-0001-8546-1161
Michael P MendenHelmholtz Zentrum München GmbH - German Research Center for Environmental Health, Institute of Computational Biology, Neuherberg, Germany.ORCID 0000-0003-0267-5792
Paul LingorDepartment of Neurology, Rechts der Isar Hospital, Technical University of Munich, München, Germany.ORCID 0000-0001-9362-7096

Funding

Bridging Funds from the Göttingen Graduate Center for Neurosciences, Biophysics and Molecular Biosciences (LCG);Cluster of Excellence and DFG Research Center Nanoscale Microscopy and Molecular Physiology of the Brain, Göttingen, Germany (PL).
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is the second most common neurodegenerative disorder whose prevalence is rapidly increasing worldwide. The molecular mechanisms underpinning the pathophysiology of sporadic PD remain incompletely understood. Therefore, causative therapies are still elusive. To obtain a more integrative view of disease-mediated alterations, we investigated the molecular landscape of PD in human post-mortem midbrains, a region that is highly affected during the disease process.

methodsTissue from 19 PD patients and 12 controls were obtained from the Parkinson's UK Brain Bank and subjected to multi-omic analyses: small and total RNA sequencing was performed on an Illumina's HiSeq4000, while proteomics experiments were performed in a hybrid triple quadrupole-time of flight mass spectrometer (TripleTOF5600+) following quantitative sequential window acquisition of all theoretical mass spectra. Differential expression analyses were performed with customized frameworks based on DESeq2 (for RNA sequencing) and with Perseus v.1.5.6.0 (for proteomics). Custom pipelines in R were used for integrative studies.

resultsOur analyses revealed multiple deregulated molecular targets linked to known disease mechanisms in PD as well as to novel processes. We have identified and experimentally validated (quantitative real-time polymerase chain reaction/western blotting) several PD-deregulated molecular candidates, including miR-539-3p, miR-376a-5p, miR-218-5p and miR-369-3p, the valid miRNA-mRNA interacting pairs miR-218-5p/RAB6C and miR-369-3p/GTF2H3, as well as multiple proteins, such as CHI3L1, HSPA1B, FNIP2 and TH. Vertical integration of multi-omic analyses allowed validating disease-mediated alterations across different molecular layers. Next to the identification of individual molecular targets in all explored omics layers, functional annotation of differentially expressed molecules showed an enrichment of pathways related to neuroinflammation, mitochondrial dysfunction and defects in synaptic function.

conclusionsThis comprehensive assessment of PD-affected and control human midbrains revealed multiple molecular targets and networks that are relevant to the disease mechanism of advanced PD. The integrative analyses of multiple omics layers underscore the importance of neuroinflammation, immune response activation, mitochondrial and synaptic dysfunction as putative therapeutic targets for advanced PD.

Indexed as

AgedAged, 80 and overFemaleHumansMaleMesencephalonMiddle AgedMolecular Targeted TherapyParkinson DiseaseReal-Time Polymerase Chain ReactionUnited Kingdomdata integrationmiRNAsmulti-omicsParkinson disease

Identifiers

PMID35090094
PMCPMC8797064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.